Lincoln Pharmaceuticals Ltd (LINCOLN) — shareholding pattern, promoter holding, financials and share price
About Lincoln Pharmaceuticals Ltd (LINCOLN)
Lincoln Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as LINCOLN and on the BSE under scrip code 531633. Its ISIN is INE405C01035.
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
Lincoln Pharmaceuticals Limited is an India-based manufacturer and marketer of pharmaceutical formulations across anti-infective, respiratory, gynecology, cardio/CNS, antidiabetic and other therapy areas, operating multiple manufacturing lines including tablets, injectables and parenterals and focused on branded generics plus export markets.
Q3 FY26 headline performance strengthened: standalone quarter revenue INR 166.32 crore, EBITDA INR 38.74 crore and PAT INR 28.60 crore, while management reaffirmed a mid-teens EBITDA margin target (15% base, targeting up to 18%) and a long-term INR 1,000 crore revenue aspiration with a small timing caveat.
Listed peers in Pharmaceuticals: Fredun Pharmaceuticals Ltd, Syncom Formulations (India) Ltd, Accent Microcell Ltd, Fermenta Biotech Ltd, Bajaj Healthcare Ltd, Themis Medicare Ltd.
Valuation & Returns
10 Jul 2026At ₹615.15 a share on 10 Jul 2026, Lincoln Pharmaceuticals Ltd (LINCOLN) was valued at a price-to-earnings ratio of 14.02x against an industry P/E of 36.41x and a price-to-book of 1.83x on a book value of ₹335.34 per share as of Mar 2025. Solomo computes return on equity of 13.09% and return on capital employed of 17.36% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 14.02x
- Industry P/E
- 36.41x
- P/B
- 1.83x
- EPS (TTM)
- ₹43.88
- Book value / share
- ₹335.34
- ROE
- 13.09%
- ROCE
- 17.36%
- ROA
- 11.03%
- Debt / equity
- 0x
- Dividend yield
- 0.29%
- EBITDA margin
- 19.54%
- 52-week range
- ₹439.95 – ₹770
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Lincoln Pharmaceuticals Ltd (LINCOLN) reported revenue of ₹671 crore, net profit of ₹88 crore and earnings per share of ₹43.88. That compares with revenue of ₹623 crore and net profit of ₹82 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹187 crore and net profit ₹12 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 472 | 510 | 581 | 623 | 671 |
| Net profit (₹ cr) | 69 | 73 | 93 | 82 | 88 |
| EPS (₹) | 34.63 | 36.4 | 46.58 | 41.11 | 43.88 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.83% | 10.63% | 9.70% | 7.35% |
| Profit growth | 15.94% | 10.69% | 5.89% | -11.74% |
| Stock price CAGR | 13% | 10% | 15% | 8% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.78% of Lincoln Pharmaceuticals Ltd (LINCOLN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.6% and domestic institutional investors (DII) hold 0.27%. Market capitalisation was ₹1,232 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 2.86%, Kishor M. Shah 2.39%, Rimo Capital Fund Lp 1.35%, Dheeraj Kumar Lohia 1.24%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.78% | - | 4.6% | 0.27% | 50.22% |
| Mar 2026 | 49.78% | - | 5.19% | 1.09% | 50.22% |
| Dec 2025 | 49.78% | - | 4.7% | 0.01% | 50.22% |
| Sep 2025 | 49.78% | - | 4.72% | 0.01% | 50.22% |
| Jun 2025 | 49.78% | - | 5.14% | 0.01% | 50.22% |
| Mar 2025 | 49.78% | - | 5% | 0.01% | 50.22% |
| Dec 2024 | 49.78% | - | 5.16% | 0% | 50.22% |
| Sep 2024 | 49.78% | - | 5.19% | 0% | 50.22% |